Leveraging biomaterials for enhancing T cell immunotherapy. 2022

Ziyan Liao, and Wentao Zhang, and Hanqi Zheng, and Yanfang Wang, and Jicheng Yu, and Hongjun Li, and Zhen Gu
Key Laboratory of Advanced Drug Delivery Systems of Zhejiang Province, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.

The dynamic roles of T cells in the immune system to recognize and destroy the infected or mutated cells render T cell therapy a prospective treatment for a variety of diseases including cancer, autoimmune diseases, and allograft rejection. However, the clinical applications of T cell therapy remain unsatisfactory due to the tedious manufacturing process, off-target cytotoxicity, poor cell persistence, and associated adverse effects. To this end, various biomaterials have been introduced to enhance T cell therapy by facilitating proliferation, enhancing local enrichment, prolonging retention, and alleviating side effects. This review highlights the design strategies of biomaterials developed for T cell expansion, enrichment, and delivery as well as their corresponding therapeutic effects. The prospects of biomaterials for enhancing T cell immunotherapy are also discussed in this review.

UI MeSH Term Description Entries
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001672 Biocompatible Materials Synthetic or natural materials, other than DRUGS, that are used to replace or repair any body TISSUES or bodily function. Biomaterials,Bioartificial Materials,Hemocompatible Materials,Bioartificial Material,Biocompatible Material,Biomaterial,Hemocompatible Material,Material, Bioartificial,Material, Biocompatible,Material, Hemocompatible
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte

Related Publications

Ziyan Liao, and Wentao Zhang, and Hanqi Zheng, and Yanfang Wang, and Jicheng Yu, and Hongjun Li, and Zhen Gu
June 2023, Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences,
Ziyan Liao, and Wentao Zhang, and Hanqi Zheng, and Yanfang Wang, and Jicheng Yu, and Hongjun Li, and Zhen Gu
October 2019, Biomaterials,
Ziyan Liao, and Wentao Zhang, and Hanqi Zheng, and Yanfang Wang, and Jicheng Yu, and Hongjun Li, and Zhen Gu
January 2021, Biomaterials,
Ziyan Liao, and Wentao Zhang, and Hanqi Zheng, and Yanfang Wang, and Jicheng Yu, and Hongjun Li, and Zhen Gu
January 2013, Cold Spring Harbor symposia on quantitative biology,
Ziyan Liao, and Wentao Zhang, and Hanqi Zheng, and Yanfang Wang, and Jicheng Yu, and Hongjun Li, and Zhen Gu
February 2016, Seminars in immunology,
Ziyan Liao, and Wentao Zhang, and Hanqi Zheng, and Yanfang Wang, and Jicheng Yu, and Hongjun Li, and Zhen Gu
February 2019, Immunotherapy,
Ziyan Liao, and Wentao Zhang, and Hanqi Zheng, and Yanfang Wang, and Jicheng Yu, and Hongjun Li, and Zhen Gu
January 2011, Immunotherapy,
Ziyan Liao, and Wentao Zhang, and Hanqi Zheng, and Yanfang Wang, and Jicheng Yu, and Hongjun Li, and Zhen Gu
December 2022, APL bioengineering,
Ziyan Liao, and Wentao Zhang, and Hanqi Zheng, and Yanfang Wang, and Jicheng Yu, and Hongjun Li, and Zhen Gu
August 2021, Polymers,
Ziyan Liao, and Wentao Zhang, and Hanqi Zheng, and Yanfang Wang, and Jicheng Yu, and Hongjun Li, and Zhen Gu
February 2017, Translational stroke research,
Copied contents to your clipboard!